Starton Therapeutics doses first patient in Phase 2a trial of STAR-LLD for multiple myeloma

The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.

Boehringer Ingelheim India appoints Meenal Gauri as Managing Director

Meenal brings in more than 16 years of international experience across Europe, Asia and the Middle East

Ultragenyx bags FDA priority review for groundbreaking GSDIa gene therapy

If approved, DTX401 would be the first treatment to address the disease at its root cause

FDA approves Lilly's Zepbound multi-dose KwikPen for obesity treatment

In 2025, over 1 million patients accessed Lilly treatments through LillyDirect

Zelluna gets green light for first-in-human trial of groundbreaking TCR-NK cancer therapy

The study will test the company’s lead product, ZI-MA4-1, in patients with advanced solid cancers

FDA nod to AstraZeneca’s all-oral, fixed-duration therapy for CLL & SLL

The decision follows compelling data from the AMPLIFY Phase III trial, demonstrating that 77% of patients receiving the Calquence-venetoclax combination were progression-free at three years

BriaCell spins off sCD80 cancer therapy to BriaPro in strategic deal

Lupin receives European Commission approval for biosimilar Ranibizumab

FDA greenlights first all-oral, fixed-duration combo therapy for untreated CLL patients

The approval, based on results from the Phase 3 AMPLIFY trial, marks the first all-oral, fixed-duration regimen for first-line CLL therapy

FDA accepts Roche’s new drug application for Giredestrant in advanced breast cancer

The NDA filing is supported by results from the phase III evERA Breast Cancer study